Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Cogent Biosciences, Inc.

COGT Nasdaq Pharmaceutical Preparations Financials FY2017–FY2025

Add to portfolio Download report

Last close Β· Oct 23, 2026

$31.21

0.3%

What Cogent Biosciences, Inc. does

COGT Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
Cogent Biosciences, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Feb 17, 2026
Accession Β· CIK
0001193125-26-053334 Β· 0001622229

Earnings calendar Β· Cogent Biosciences, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Cogent Biosciences, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 6, 2026

Friday Β· in 11 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.57
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 10, 2026 Q2 '26 Before the market opens 8-K β†—
May 5, 2026 Q1 '26 Before the market opens 8-K β†—
Feb 17, 2026 Q4 '25 Before the market opens 8-K β†—
Nov 3, 2025 Q3 '25 Before the market opens 8-K β†—
Jul 7, 2025 Q2 '25 Time not announced 8-K β†—
May 6, 2025 Q1 '25 Before the market opens 8-K β†—
Feb 25, 2025 Q4 '24 Before the market opens 8-K β†—
Nov 12, 2024 Q3 '24 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Cogent Biosciences, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

1 strength 3 to watch

Cogent Biosciences, Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$329M

No. It lost money last year.

Weak

How healthy are the accounts?

3 / 7

Weak. It passes 3 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$5.3B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$2.16 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Cogent Biosciences, Inc. lost $329M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$266M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Cogent Biosciences, Inc. lost $329M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$266M in fiscal 2025, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders sold $384M of shares on the open market and bought none.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$384M

6 insiders

Of sales under plans

0%

$1.7M

DateInsiderTradeSharesPriceValueFiling
Aug 27, 2026 Arlene MorrisDirector Sold plan 45,510 $37.12 $1.7M Form 4
Mar 31, 2026 Fairmount Funds Management LLCDirector Sold 7,000,000 $34.66 $243M Form 4
Jan 22, 2026 Fairmount Funds Management LLCDirector Sold 3,500,000 $36.40 $127M Form 4
Dec 26, 2025 Evan KearnsChief Legal Officer Sold 65,000 $38.70 $2.5M Form 4
Dec 26, 2025 Jessica SachsChief Medical Officer Sold 82,642 $38.70 $3.2M Form 4
Dec 26, 2025 John Edward RobinsonChief Scientific Officer Sold 90,000 $38.74 $3.5M Form 4
Dec 26, 2025 John L. GreenChief Financial Officer Sold 77,000 $38.68 $3.0M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Cogent Biosciences, Inc. has $678M more cash than debt.

Cash, debt and the ratios that show how comfortably Cogent Biosciences, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $220M$259M$266M$287M$901M
Debt incl. finance leases β€”β€”β€”$0.0M$223M
Debt / equity β€”β€”β€”0.0x0.4x
Interest coverage β€”β€”β€”β€”βˆ’108.9x
Current ratio 13.0x9.9x7.1x5.3x14.2x
Quick ratio 13.0x9.9x7.1x5.3x14.2x
Total assets $232M$301M$313M$328M$938M
Total liabilities $17.9M$45.1M$55.6M$71.6M$301M
Shareholders' equity $214M$256M$258M$256M$636M
Net debt (βˆ’ = net cash) β€”β€”β€”βˆ’$287Mβˆ’$678M

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Cogent Biosciences, Inc. passes 3 of 7 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ• βœ“ βœ• βœ• βœ• βœ• βœ“
Cash from operations exceeds net income βœ• βœ“ βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€” β€” βœ•
Current ratio rose β€” βœ• βœ• βœ“ βœ• βœ• βœ• βœ• βœ“
Share count didn't rise β€” βœ• βœ“ βœ• βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” βœ• βœ“ βœ• β€” β€” β€” β€” β€”
F-score β€” / 32 / 72 / 73 / 7β€” / 6β€” / 6β€” / 6β€” / 63 / 7
Accruals ratio 0.7%βˆ’3.0%14.3%βˆ’25.9%βˆ’5.6%βˆ’8.1%βˆ’12.6%βˆ’15.0%βˆ’10.2%
Altman Z'' βˆ’5.280.43βˆ’7.0316.4412.373.39βˆ’1.01βˆ’5.631.62

All figures

Every number, year by year.

9 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $8.4M $9.7M $22.5M $7.9M β€” β€” β€” β€” β€”
Research and development $29.8M $38.3M $43.7M $25.7M $55.9M $122M $174M $233M $270M
Operating income βˆ’$26.2M βˆ’$36.0M βˆ’$32.2M βˆ’$82.2M βˆ’$75.6M βˆ’$148M βˆ’$208M βˆ’$276M βˆ’$333M
Interest expense β€” β€” β€” β€” β€” β€” β€” β€” $3.1M
Income tax β€” β€” β€” β€” β€” β€” β€” β€” $0.0M
Net income βˆ’$25.5M βˆ’$34.5M βˆ’$31.8M βˆ’$74.8M βˆ’$72.3M βˆ’$140M βˆ’$192M βˆ’$256M βˆ’$329M
Net income to common βˆ’$25.6M βˆ’$34.5M βˆ’$31.8M βˆ’$179M βˆ’$72.3M βˆ’$140M βˆ’$192M β€” β€”
Diluted EPS βˆ’$2.51 βˆ’$1.39 βˆ’$4.18 βˆ’$16.17 βˆ’$1.87 βˆ’$1.73 βˆ’$1.94 βˆ’$1.94 βˆ’$2.16
Diluted shares 0.01B 0.02B 0.01B 0.01B 0.04B 0.06B 0.08B 0.10B 0.13B
Cash flow
Cash from operations βˆ’$25.8M βˆ’$32.5M βˆ’$41.5M βˆ’$35.9M βˆ’$58.8M βˆ’$119M βˆ’$154M βˆ’$208M βˆ’$264M
Capital expenditure $0.9M $0.5M $0.0M β€” $1.7M $6.9M $2.8M $0.6M $1.6M
Free cash flow βˆ’$26.7M βˆ’$33.0M βˆ’$41.5M β€” βˆ’$60.5M βˆ’$126M βˆ’$156M βˆ’$208M βˆ’$266M
Depreciation and amortization $1.2M $1.3M $1.3M $0.7M $0.1M $0.8M $2.3M $2.5M $2.6M
Stock-based compensation $1.3M $3.1M $3.2M $6.0M $11.7M $18.4M $30.6M $39.7M $46.1M
Balance sheet
Cash and short-term investments $41.0M $55.7M $37.4M $242M $220M $259M $266M $287M $901M
Total debt β€” β€” β€” β€” β€” β€” β€” $0.0M $223M
Current assets $42.4M $81.0M $40.6M $245M $223M $265M $271M $296M $910M
Current liabilities $11.2M $24.9M $13.2M $13.1M $17.1M $26.8M $38.2M $55.7M $64.0M
Property and equipment, net $4.1M $3.3M $1.9M $0.1M $1.7M $7.8M $8.3M $6.5M $5.5M
Total assets $49.1M $85.9M $49.4M $251M $232M $301M $313M $328M $938M
Total liabilities $20.8M $25.7M $17.7M $16.2M $17.9M $45.1M $55.6M $71.6M $301M
Shareholders' equity βˆ’$48.8M $60.2M $31.8M $235M $214M $256M $258M $256M $636M
Margins
Operating margin βˆ’312.8% βˆ’369.9% βˆ’143.0% βˆ’1,044.3% β€” β€” β€” β€” β€”
EBITDA margin βˆ’298.8% βˆ’356.3% βˆ’137.3% βˆ’1,035.2% β€” β€” β€” β€” β€”
Net margin βˆ’304.9% βˆ’354.8% βˆ’141.5% βˆ’950.4% β€” β€” β€” β€” β€”
FCF margin βˆ’319.9% βˆ’339.4% βˆ’184.7% β€” β€” β€” β€” β€” β€”
Returns
Return on capital employed βˆ’69.0% βˆ’59.0% βˆ’89.0% βˆ’34.6% βˆ’35.1% βˆ’54.0% βˆ’75.6% βˆ’101.4% βˆ’38.2%
Return on equity β€” βˆ’606.5% βˆ’69.2% βˆ’56.2% βˆ’32.2% βˆ’59.7% βˆ’74.9% βˆ’99.5% βˆ’73.7%
Return on assets βˆ’51.9% βˆ’51.1% βˆ’47.0% βˆ’49.8% βˆ’29.9% βˆ’52.6% βˆ’62.6% βˆ’79.8% βˆ’52.0%
Return on tangible equity β€” βˆ’57.4% βˆ’100.2% βˆ’76.4% βˆ’33.7% βˆ’54.8% βˆ’74.6% βˆ’99.8% βˆ’51.7%
Growth
Revenue growth β€” 16.4% 131.1% βˆ’65.0% β€” β€” β€” β€” β€”
Share count change β€” 144.3% βˆ’69.4% 45.4% 249.5% 51.7% 35.6% 30.4% 24.1%
Financial health
Debt / equity β€” β€” β€” β€” β€” β€” β€” 0.0x 0.4x
Interest coverage β€” β€” β€” β€” β€” β€” β€” β€” βˆ’108.9x
Current ratio 3.8x 3.2x 3.1x 18.7x 13.0x 9.9x 7.1x 5.3x 14.2x
Quick ratio 3.8x 3.2x 3.1x 18.7x 13.0x 9.9x 7.1x 5.3x 14.2x
Capital allocation
Capex / revenue 10.9% 5.6% 0.1% β€” β€” β€” β€” β€” β€”
Stock comp / revenue 16.0% 31.7% 14.4% 76.4% β€” β€” β€” β€” β€”
Quality scores
Piotroski F-score β€” 2.0 2.0 3.0 β€” β€” β€” β€” 3.0
Altman Z'' βˆ’5.3 0.4 βˆ’7.0 16.4 12.4 3.4 βˆ’1.0 βˆ’5.6 1.6
Accruals ratio 0.7% βˆ’3.0% 14.3% βˆ’25.9% βˆ’5.6% βˆ’8.1% βˆ’12.6% βˆ’15.0% βˆ’10.2%

Source: SEC EDGAR XBRL filings (CIK 0001622229). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open